A European view on the North American fifth consensus on antithrombotic therapy

Chest

Volumn 117, Issue 6, 2000, Pages 1755-1770

  Verstraete, Marc ^a   Prentice, Colin R M ^b   Samama, Michel ^c   Verhaeghe, Raymond ^a   Bell, P R F ^d   Bertrand, M E ^e   Bergqvist, D ^e   Bounameaux, H ^e   Bousser, M G ^e   Buller H ^e   Butchart, E G ^f   Coccheri, S ^e   Cohen, A ^g   Conard, J ^e   De Bono, D ^d   Forbes, C D ^h   Haas, S ^e   Hampton, J ⁱ   Hellgren, M ^e   Koudstaal, P J ^e   Kreuz, W ^e   Lammle B ^e   Lechner, K ^e   Levy, S ^e   Lip, G Y P ^j   Lowe, G ^k   Michel, J P ^e   Montalescot, G ^e   More, R S ^g   Petersen, P ^e   Pfisterer, M ^e   Planes, A ^e   Pini, M ^e   Prandoni, P ^e   Prentice, C ^l   Robberecht, W ^e   Samama, M ^e   Sutor, A H ^e   Simoons, M L ^e   Taylor, G P ^g   Van Der Meer, J ^e   Van De Werf, F ^e   Van Geet, C ^e   Van Gyn, J ^e   Verhaeghe, R ^e   Verheugt, F W A ^e   Verstraete, M ^e   Walker, I ^k   Wallentin, L ^e   more..

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c HÔTEL DIEU   (France)

^d Leicester Hospitals   (United Kingdom)

^e NONE   (Sweden)

^f Cardiff Medical School   (United Kingdom)

^g London Center   (United Kingdom)

^h Dundee College   (United Kingdom)

ⁱ Nottingham   (United Kingdom)

^j Birmingham   (United Kingdom)

^k Glasgow   (United Kingdom)

^l Leeds Hospital   (United Kingdom)

more..

Author keywords

Antithrombotic agents; Coumarin drugs; Heparin; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; DEXTRAN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROUROKINASE; RETEPLASE; STREPTOKINASE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERY BYPASS; ARTICLE; BIOEQUIVALENCE; BLOOD CLOT LYSIS; CHEMOPROPHYLAXIS; CHILDHOOD DISEASE; CLINICAL TRIAL; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG INDICATION; GRAFT PATENCY; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREGNANCY; PRIORITY JOURNAL; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; VALVULAR HEART DISEASE;

EID: 0034097868     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.6.1755     Document Type: Article

References (99)

1. 1 Dalen JE, Hirsh J. American College of Chest Physicians Conference on Antithrombotic Therapy. Chest 1998; 114: 439S-767S
2. 2 Ginsburg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1998; 114:524S-530S
3. 3 Nordstrom M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232:155-160
4. 4 Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179:1324-1328
5. 5 Blombäck M, Bremme K, Hellgren M, et al. Thromboprophylaxis with low molecular mass heparin, Fragmin (dalteparin), during pregnancy: a longitudinal safety study. Blood Coagul Fibrinolysis 1998; 9:1-9
6. 6 Sanson BJ, Lensing AWA, Prins MH, et al. Safety of low molecular weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81:668-672
7. 7 Brennand JE, Walker ID, Greer IA. Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with Enoxaparin. Acta Hematol 1999; 101:53-55
8. 8 Blombäck M, Bremme K, Hellgren M, et al. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagul Fibrinolysis 1998; 9:343-350
9. 9 Thomson AJ, Walker ID, Greer IA. Low molecular weight heparin for immediate management of thromboembolic disease in pregnancy [letter]. Lancet 1998; 352:1904
10. 10 Watson WJ, Freeman J, O'Brien C, et al. Embolic stroke in a pregnant patient with a mechanical heart valve on optimal heparin therapy. Am J Perinatal 1996; 13:371-372
11. 11 Tam WH, Wong KS, Yuen PM, et al. Low molecular weight heparin and thromboembolism in pregnancy [letter]. Lancet 1999; 353:932
12. 12 Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77:39-43
13. 13 Dulitzki M, Pauzner R, Landevitz P, et al. Low molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 77: 39-43
14. 14 Clagett GP, Andersson FA, Geerts W, et al. Prevention of venous thromboembolism. Chest 1998; 114(suppl):531S-560S
15. 15 Prentice CRM. Are symptomatic endpoints acceptable in venous thromboprophylactic studies? Haemostasis 1998; 28(suppl3):109-112
16. 16 Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement: a series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg Br 1995; 77:6-10
17. 17 Fender D, Harper WM, Thompson JR, et al. Mortality and fatal pulmonary embolism post primary total hip replacement: results from a regional hip register. J Bone Joint Surg Br 1997; 79:896-899
18. 18 The Pulmonary Embolism Prevention (PEP) Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: the Pulmonary Embolism Prevention (PET) trial. Lancet 2000; 355:1295-1302
19. 19 Samama MM, Cohen AT, Darmon JY, et al, for the Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 34:793-800
20. 20 Murray DW, Carr AJ, Bulstrode CJK. Pharmacological thromboprophylaxis and total hip replacement. J Bone Joint Surg Br 1995; 77:3-5
21. 21 Handoll HHG, Farrar MJ, McBirnie J, et al. Prophylaxis using heparin, low molecular weight heparin and physical methods against deep vein thrombosis and pulmonary embolism in hip fracture surgery. Cochrane Library 1998; Issue 1. Oxford, UK: Update Software
22. 22 Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114(suppl): 561S-578S
23. 23 Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contra-indications to coumarin. Thromb Haemost 1994; 71:7-11
24. 24 Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72:191-197
25. 25 Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999; 81:26-31
26. 26 Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336:393-398
27. 27 Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7
28. 28 Goldhaber SZ. Pulmonary embolism. N Engl J Med 1998; 399:93-94
29. 29 Laupacis A, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114(suppl):579S-589S
30. 30 Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-1457
31. 31 Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation. Arch Intern Med 1998; 158:1316-1320
32. 32 Lip GYH. Thromboprophylaxis for atrial fibrillation. Lancet 1999; 353:4-6
33. 33 Lip GYH. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk? Lancet 1997; 349:1565-1566
34. 34 SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with non valvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279:1673-1677
35. 35 Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998; 352:1167-1171
36. 36 Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation-III randomised clinical trial. Lancet 1996; 348:633-638
37. 37 The European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993; 342:1255-1262
38. 38 Van Latum JC, Koudstaal PJ, van Kooten F, et al. Predictors of major vascular events in patients with a transient ischemic attack or nondisabling stroke and with nonrheumatic atrial fibrillation. Stroke 1995; 26:801-806
39. 39 Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998; 128:639-647
40. 40 Salem DN, Levine HJ, Pauker SG, et al. Antithrombotic therapy in valvular heart disease. Chest 1998; 114(suppl): 590S-601S
41. 41 Maze SS, Kotler MN, Parry WR. Flow characteristics in the dilated left ventricle with thrombus: qualitative and quantitative Doppler analysis. J Am Coll Cardiol 1989; 13:873-881
42. 42 Movsovitz C, Movsowitz HD, Jacobs LE, et al. Significant mitral regurgitation is protective against left atrial spontaneous echo contrast and thrombus as assessed by transesophageal echocardiography. J Am Soc Echocardiogr 1993; 6:107-114
43. 43 Stein PD, Alpert JS, Dalen JE, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1998; 114(suppl):602S-610S
44. 44 Dalen JE, Hirsh J. Introduction: antithrombotic therapy-the evolving consensus: 1986 to 1988. Chest 1998; 114(suppl): 439S-440S
45. 45 Grunkemeier GL, Starr A, Rahimtoola SH. Prosthetic heart valve performance: long-term follow-up. Curr Probl Cardiol 1992; 17:331-406
46. 46 Butchart EG, Moreno de la Santa P, Rooney SJ, et al. Arterial risk factors and ischemic cerebrovascular events after aortic valve replacement. J Heart Valve Dis 1995; 4:1-8
47. 47 Bamford J, Sandercook P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337:1521-1526
48. 48 Butchart EG. Thrombogenicity, thrombosis and embolism. In: Butchart EG, Bodnar E, eds. Current issues in heart valve disease: thrombosis, embolism and bleeding. London, UK: ICR Publishers, 1992:172-205
49. 49 Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992; 102(suppl):445S-455S
50. 50 Horstkotte D, Schulte HD, Bircks W, et al. Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude medical prosthesis. J Thorac Cardiovasc Surg 1994; 107:1136-1145
51. 51 Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333:11-17
52. 52 Pouleur H, Buyse M. Effects of dipyridamole in combination with anticoagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves: a meta-analysis of the randomized trials. J Thorac Cardiovasc Surg 1995; 110:463-472
53. 53 Cappelleri JC, Fiore L, Brophy M, et al. Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: a meta-analysis. Am Heart J 1995; 130:547-552
54. 54 Cairns JA, Théroux P, Lewis HD, et al. Antithrombotic agents in coronary artery disease. Chest 1998; 114(suppl):611S-633S
55. 55 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii:349-360
56. 56 The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339:436-443
57. 57 The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by unstable Signs and Symptoms (PRISM-Plus) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338:1488-1495
58. 58 Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999; 340:1623-1629
59. 59 Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-452
60. 60 Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B study. Circulation 1999; 99:1593-1601
61. 61 Fragmin, and Fast Revascularisation during Instable Artery Disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354:708-715
62. 62 Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762
63. 63 Cairns JA, Kennedy JW, Fuster V. Coronary thrombolysis. Chest 1998; 114(suppl):634S-657S
64. 64 ISIS-1 (First International Study of Infarct Survival) Collaborative Study Group. Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. Lancet 1988; I:921-923
65. 65 Olsson G, Oden A, Johanson L, et al. Prognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2-7 year follow-up. Eur Heart J 1988; 9:365-372
66. 66 Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience; global utilization of streptokinase and TPA (alteplase) for occluded coronary arteries. J Am Coll Cardiol 1098; 32:634-640
67. 67 Bode C, Smalling W, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996; 94:891-898
68. 68 International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346:329-336
69. 69 The Continuous Infusion Versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997; 337:1124-1130
70. 70 Assessment of the Safety, and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354:716-722
71. 71 Antman EM, Wilcox RG, Giugliano RP, et al. Long-term comparison of lanoteplase and alteplase in ST elevation myocardial infarction: 6 months follow-up in InTIME II trial [abstract]. Circulation 1999; 100:I-498
72. 72 Stein PD, Dalen JE, Goldman S, et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 1998; 114(suppl):658S-665S
73. 73 Sanz G, Pajaron A, Alegria E, et al. Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Circulation 1990; 182:765-773
74. 74 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy -III. Br Med J 1994; 308:81-106/159-168/235-246
75. 75 The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336:153-162
76. 76 Caprie Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348:1329-1339
77. 77 van der Meer J, Hillege HL, van Gilst WH, et al. A comparison of internal mammary artery and saphenous vein grafts after coronary artery bypass surgery: no difference in one-year occlusion rates and clinical outcome. Circulation 1994; 90:2367-2374
78. 78 Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 1998; 114(suppl):660S-682S
79. 79 Harker LR, Boissel JP, Pilgrin AJ, et al. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. Drug Saf 1999; 4:325-335
80. 80 The STILE Investigators. Results of a prospective randomised trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial. Ann Surg 1994; 220:251-268
81. 81 Albers GW, Easton JD, Sacco RL, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998; 114(suppl):683S-698S
82. 82 Furlan AJ. PROACT II: recombinant pro-urokinase (r-ProUK) in acute cerebral thromboembolism: initial trial results; the PROACT II investigators [abstract]. Stroke 1999; 30:234
83. 83 Albers GW. Prospective, monitored, multicenter, post-approval experience with intravenous t-PA for treatment of acute stroke: the Standard Treatment with Activase to Reverse Stroke (STARS) Study [abstract]. Stroke 1999; 30:244
84. 84 Clark WM, Albers GW. The ATLANTIS rt-PA (alteplase) Acute Stroke Trial: final results [abstract]. Stroke 1999; 30:234
85. 85 Hacke W, Kaste M, Fieschi C, et al. Randomised doubleblind trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998; 352:1245-1251
86. 86 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischemic stroke. Lancet 1997; 349:1569-1581
87. 87 CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997; 349:1641-1649
88. 88 Einhäupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338:597-600
89. 89 De Bruijn SFTM, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999; 30:484-488
90. 90 Diener H, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1-13
91. 91 Hass WK, Easton JD, Adam HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: the Ticlopidin Aspirin Stroke Study Group. N Engl J Med 1989; 321:501-507
92. 92 Popma JJ, Weitz J, Bittle JA, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998; 114(suppl):728S-741S
93. 93 Brack MJ, Ray S, Chauhan A, et al. Results of a multicenter randomised trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome: the Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. J Am Coll Cardiol 1995; 26:947-954
94. 94 Schomig A, Neumann FJ, Kastra A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary stents. N Engl J Med 1996; 334:1084-1089
95. 95 Bertrand MF, Legrand V, Boland J, et al. Randomised multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998; 98:1597-1603
96. 96 Urban P, Macaya C, Rupprecht H, et al. Randomised evaluation of anticoagulant versus antiplatelet therapy after coronary stent implantation in high risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98:2126-2132
97. 97 Bertrand ME, Rupprecht HJ, Urban P, et al. Comparative safety of ticlopidine and clopidogrel in coronary stent patients: data from CLASICS [abstract]. Circulation 1999; 100:I-620
98. 98 Michelson AD, Bovil E, Monagle P, et al. Antithrombotic therapy in children. Chest 1998; 114(suppl):748S-769S
99. 99 Sutor AH, Massicotte P, Leaker M, et al. Heparin therapy in pediatric patients. Semin Thromb Hemost 1997; 23:303-320